Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib

A. Zhou, E. M. Knoche, E. K. Engle, D. A.C. Fisher, S. T. Oh

Research output: Contribution to journalArticlepeer-review

23 Scopus citations
Original languageEnglish
Pages (from-to)e351
JournalBlood cancer journal
Volume5
DOIs
StatePublished - Oct 2 2015

Cite this